Cart
sales@molnova.com
Rociclovir PM
CAS No. 89419-23-8
Rociclovir PM( —— )
Catalog No. M35999 CAS No. 89419-23-8
Rociclovir PM (2-[(2-aminopurin-9-yl)methoxy]propane-1,3-diol) is a compound with antiviral activity
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 266 | In Stock |
|
| 5MG | 273 | In Stock |
|
| 10MG | 372 | In Stock |
|
| 25MG | 563 | In Stock |
|
| 50MG | 742 | In Stock |
|
| 100MG | 977 | In Stock |
|
| 200MG | 1293 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRociclovir PM
-
NoteResearch use only, not for human use.
-
Brief DescriptionRociclovir PM (2-[(2-aminopurin-9-yl)methoxy]propane-1,3-diol) is a compound with antiviral activity
-
DescriptionRociclovir PM (2-[(2-aminopurin-9-yl)methoxy]propane-1,3-diol) is a compound with antiviral activity
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetAntiviral
-
RecptorAntiviral
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number89419-23-8
-
Formula Weight239.23
-
Molecular FormulaC9H13N5O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(OC(CO)CO)N1C=2C(N=C1)=CN=C(N)N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Arbidol
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against enveloped and non-enveloped viruses, suppressing virus propagation and modulating the expression of inflammatory cytokines for use as an anti-influenza virus agent .
-
LCC-12 FA
LCC-12 FA is a dimer composed of metformin that induces a decrease in the NAD(H) pool by targeting mitochondrial copper(ii).
-
SARS-CoV-2 nsp13-IN-...
SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent inhibitor of nsp13 (non-structural protein 13), selectively inhibiting nsp13 ssDNA+ATPase with an IC50 of 6 μM, but not ssDNA-ATPase, and can be used to study COVID-19.
